Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 5/1/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Mario Peres?

Mario F.P. Peres

Director

São Paulo Headache Center

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Background Information

Employment History

Hospital Albert Einstein


Affiliations

American College of Physicians

Fellow


American Academy of Neurology

Member


Brazilian Headache Society

Member


International Headache Society

Member


Education

MD


Web References(15 Total References)


About Our Experts Dr. Mario Peres || Migraine Survival

www.migrainesurvival.com [cached]

About Our Experts - Mario Peres MD
Dr. Mario Peres Mario Peres, M.D. Director of the São Paulo Headache Center, and Professor of Neurology at ABC Medical School. He is a member of the American Academy of Neurology, Brazilian Headache Society, International Headache Society, and a Fellow of the American College of Physicians. Dr. Peres currently serves as a reviewer for the journals Headache, Cephalalgia, Arquivos de Neuropsiquiatrica, and Journal of Psychosomatic Research. Dr. Peres is a Senior Research Associate at the Brain Research Institute - Albert Einstein Hospital and has research interests in sleep disorders and psychiatric comorbidities in headache. Dr. Peres' websites are www.cefaleas.com and http://dordecabeca.net


Board Of Experts In Migraine Headache Related Fields || Migraine Survival

www.migrainesurvival.com [cached]

Mario Peres, M.D.
Director of the São Paulo Headache Center, and Professor of Neurology at ABC Medical School. He is a member of the American Academy of Neurology, Brazilian Headache Society, International Headache Society, and a Fellow of the American College of Physicians. Dr. Peres currently serves as a reviewer for the journals Headache, Cephalalgia, Arquivos de Neuropsiquiatrica, and Journal of Psychosomatic Research. Dr. Peres is a Senior Research Associate at the Brain Research Institute - Albert Einstein Hospital and has research interests in sleep disorders and psychiatric comorbidities in headache.


About Our Experts Dr. Mario Peres || Migraine Survival

www.migrainesurvival.com [cached]

About Our Experts - Mario Peres MD
Dr. Mario Peres Mario Peres, M.D. Director of the São Paulo Headache Center, and Professor of Neurology at ABC Medical School. He is a member of the American Academy of Neurology, Brazilian Headache Society, International Headache Society, and a Fellow of the American College of Physicians. Dr. Peres currently serves as a reviewer for the journals Headache, Cephalalgia, Arquivos de Neuropsiquiatrica, and Journal of Psychosomatic Research. Dr. Peres is a Senior Research Associate at the Brain Research Institute - Albert Einstein Hospital and has research interests in sleep disorders and psychiatric comorbidities in headache. Dr. Peres' websites are www.cefaleas.com and http://dordecabeca.net


vitaminlady.com

Dr. Mario F. Peres, of the Sao Paulo Headache Center, Brazil, and colleagues reported in the December


gesund.ca

"Melatonin 3 mg was significantly better than placebo with no difference compared to amitriptyline with respect to migraine prevention," principal investigator Mario Peres, MD, PhD, told delegates here attending the American Academy of Neurology (AAN) 65th Annual Meeting.
"But if we look at the proportion of responders, then melatonin had better results than amitriptyline," added Dr. Peres, who is director of São Paulo Headache Center, professor of neurology at ABC Medical School, and senior research associate at the Albert Einstein Brain Research Institute, Brazil. According to Dr. Peres, melatonin's role in regulating circadian rhythm has been linked to cluster headache, hypnic headache, and migraine. Further, he noted, melatonin plays an important role in sleep regulation, and disruption of melatonin production has been linked to sleep disorders, including sleep apnea, insomnia, and delayed sleep phase syndrome, which, in turn, are linked to headache. He also noted that there is a bidirectional relationship in which headache can disrupt sleep and lead to insomnia and excessive daytime sleepiness. Finally, he pointed out that research has linked low levels of melatonin in plasma and urine and altered peak time in melatonin levels to a variety of headache types, including migraine. According to Dr. Peres, research into melatonin as a potential treatment for headache has included several case reports and open-label studies but only 2 randomized controlled trials: 1 in cluster headache, which was positive, and 1 negative trial in migraine. The negative migraine trial, he said, had several limitations, including a small sample size and a short duration of only 8 weeks. Melatonin was also "very tolerable" and had significantly fewer adverse effects compared with amitriptyline, said Dr. Peres. Daytime sleepiness was the most frequent symptom in all 3 groups but was most pronounced in the amitriptyline group (n = 24). Although patients gained weight in both the amitriptyline (n = 3) and placebo (n = 1) groups, melatonin was associated with weight loss. Timing of administration and formulation is also important. Ideally, said Dr. Peres, melatonin should be taken between 10 pm and 11 pm to mimic the physiologic peak. In addition, a fast-acting rather than a slow-release formula should be used


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory